Replies to post #2979 on AVEO Pharmaceuticals, Inc. (AVEO)

[Biotech Pharmer]

yes, but not short term. I think $7-$8 in 6 months. After positive P3 top line results and the 201710K in March will be when the afterburners kick in. But there's 3 other drugs with established development partners in the pipe and a looming AV-353 partnership to be announced. So much can happen here, and with the pending EU Fotivda sales and milestone payments from EUSA, I just don't see any downside from this level.